<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over a follow-up period of ten years, nine of our 100 patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">preleukaemia</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> occurred 19-156 (median 35) months from the diagnosis of MM </plain></SENT>
<SENT sid="2" pm="."><plain>Six patients presented with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and no patients had active MM at the time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients were defined as having refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) and six as refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e>), according to the FAB classification </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical course is characterized by increasing red blood cell and platelet transfusion requirements, <z:hpo ids='HP_0002719'>recurrent infections</z:hpo> and <z:mp ids='MP_0001914'>bleeding</z:mp> episodes </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients, except for one, died within 3 to 8 (median 5) months from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>The causes of <z:hpo ids='HP_0011420'>death</z:hpo> were <z:hpo ids='HP_0100806'>sepsis</z:hpo> or <z:mp ids='MP_0001914'>bleeding</z:mp>; three patients underwent leukaemic transformation </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, the clinical course of this small group of <z:mp ids='MP_0009440'>myeloma</z:mp> patients who developed <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> (sMDS), was similar to other series of patients with sMDS </plain></SENT>
<SENT sid="8" pm="."><plain>Serial bone marrow examinations suggest an initial hypercellular phase, followed by a rapidly evolving preterminal <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular marrow</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In an attempt to detect MM patients at risk of developing sMDS, the epidemiological (including ethnic), clinical and laboratory data of the 9 MDS patients at the time of the MM presentation were reviewed and compared to the other MM patients </plain></SENT>
<SENT sid="10" pm="."><plain>No significant differences were observed between the two groups in most parameters, except for two </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were Ashkenazi Jews and no patients of Sepharadic origin developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Also, no IgA-<z:mp ids='MP_0009440'>myeloma</z:mp> patient developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>If these findings are confirmed in a larger series, it may point to subgroups at risk which may require a different approach.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>